Eli Lilly 2007 Annual Report Download - page 110

PROXY STATEMENT
108108
ed stock grants and restricted stock units:
Group Performance Awards (Payout)
Shareholder Value Awards
(Target) 1Restricted Stock Grants / Units
Named Executive Offi cers Footnote 2 Footnote 2 None
All Executive Offi cers as a group
(10 employees) 391,218 shares 243,754 shares None
All other employees 3,577,896 shares 726,194 shares 379,176 shares
1 For 2007-2009 award period. The actual number of shares paid may vary from zero to 140 percent of target for
executive offi cers and from 40 to 140 percent of target for all other employees.
2 See page 93, narrative following Grants of Plan-Based Awards During 2007 table.
Securities Authorized for Issuance Under Equity Compensation Plans
The following table presents information as of December 31, 2007, regarding our compensation plans under which
shares of Lilly common stock have been authorized for issuance.
Plan category
(a) Number of securities to
be issued upon exercise of
outstanding options, warrants,
and rights
(b) Weighted-average exercise
price of outstanding options,
warrants, and rights
(c) Number of securities
remaining available for
future issuance under equity
compensation plans (excluding
securities refl ected in column (a))
Equity compensation plans approved
by security holders 71,953,815 $68.78 46,577,743
Equity compensation plans not
approved by security holders 1 9,195,230 $75.77 320,555
Total 81,149,045 $69.57 46,898,298
1 Represents shares in the Lilly GlobalShares Stock Plan, which permits the company to grant stock options to non-
management employees worldwide. The plan is administered by the senior vice president responsible for human
resources. The stock options are nonqualifi ed for U.S. tax purposes. The option price cannot be less than the fair
market value at the time of grant. The options shall not exceed 11 years in duration and shall be subject to vesting
schedules established by the plan administrator. There are provisions for early vesting and early termination of
the options in the event of retirement, disability, and death. In the event of stock splits or other recapitalizations,
the administrator may adjust the number of shares available for grant, the number of shares subject to outstand-
ing grants, and the exercise price of outstanding grants.
The board recommends that you vote FOR amendment of the 2002 Lilly Stock Plan.
Item 6. Shareholder Proposal Regarding International Outsourcing of Animal Research
Meredith Page, 2231 Court Ave., Memphis, Tennessee 38104, on behalf of People for the Ethical Treatment of
Animals (PeTA), 501 Front Street, Norfolk, Virginia 23510, and benefi cial owner of approximately 105 shares, has
submitted the following proposal:
Resolved, that the Board report to shareholders on the rationale for increasingly exporting the Company’s animal
experimentation to countries which have either nonexistent or substandard animal welfare regulations and little or
no enforcement. Further, the shareholders request that the report include information on the extent to which the
Company requires adherence to U.S. animal welfare standards at facilities in foreign countries.
Supporting Statement: Eli Lilly has publicly committed to an “ethical and scientifi c obligation to ensure the re-
sponsible treatment of animals used in research, to minimize the number of animals involved, and to pursue the
development of alternative test systems.”1
However, the Company is currently relocating animal research and testing to countries known for having no or
poor animal welfare standards and negligible oversight.
1 Policy statement at http://www.lilly.com/about/citizenship/key_issues/research/rd_animal.html.